by admin | Aug 24, 2021 | News
Exogenus published a study offering an in-depth look at the safety profile of umbilical cord blood-derived exosomes. Exo-101, a solution enriched in small extracellular vesicles produced by umbilical cord blood mononuclear cells (UCB-MNC-sEV), has consistently shown...
by admin | May 15, 2021 | News
Patricia Freire, one of Exogenus’ scientists, presents some of our recent advances at the ISEV Annual Meeting, happening on May 18th to 21st, virtually. The talk, entitled “Umbilical cord blood-derived small extracellular vesicles: immune-modulating properties and...
by admin | May 15, 2021 | News
Exogenus was the only Portuguese company selected to pitch at the European Innovation Council’s Investor Day on Health on May 18th and 19th to present its pioneering technology to leading Life Sciences investors from across the globe, featuring its Series A investment...
by admin | Apr 16, 2021 | News
Labiotech.eu just published an article featuring the interview with Exogenus’ CEO and CSO, Joana Correia, discussing the disparity in funding opportunities seen in Europe vs USA. The article, which also quotes Antonin de Fougerolles (Evox Therapeutics, CEO) and...
by admin | Mar 1, 2021 | News
Exosome RNA, an online publication featuring the hottest trends in global exosome research, recently highlighted Exogenus Therapeutics’ contribution to the field, by mentioning our recent publication in Stem Cells Translational Medicine. Exogenus Therapeutics...
